
Brainreader ApS
AI-powered MRI scan analysis for brain structure quantification.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor | €0.0 | round |
investor | €0.0 | round | |
N/A | €0.0 | round | |
* | €6.6m | Early VC | |
Total Funding | 000k |
EUR | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Brainreader ApS is a Danish medical technology company that develops decision support software for healthcare professionals. Founded in 2011 by Jamila Ahdidan, the company is headquartered in Aalborg, Denmark, with an office in the US. The firm's core product is Neuroreader®, an AI-driven, software-based assessment tool that provides automated volumetric analysis of brain MRI scans.
Neuroreader® is designed to assist radiologists and neurologists in the diagnosis and monitoring of neurodegenerative conditions such as Alzheimer's disease, epilepsy, and traumatic brain injuries. The software functions by automatically labeling, visualizing, and quantifying up to 83 different brain structures from an MRI scan. It then compares these measurements against an FDA-cleared database of healthy brain volumes, matched for age and gender, to detect and highlight abnormalities and atrophy. This process generates a detailed volumetric report in under 10 minutes, a significant reduction from the hours required for manual segmentation. This provides clinicians with objective, reliable, and reproducible data to aid in early diagnosis and monitor disease progression.
The business operates on a B2B Software as a Service (SaaS) model, integrating directly into existing hospital and radiology workflows, including PACS systems. Its clients include university hospitals and imaging centers across Europe and North America. The software is CE-marked and has received FDA clearance, enabling its use in clinical markets. Brainreader has secured significant funding to support its commercial expansion, particularly in the U.S. market, where new reimbursement codes for brain volumetry are creating favorable market conditions. A funding round in May 2025, led by Dahlgren Capital with participation from Investo Capital, raised $7.49 million.
Keywords: brain volumetrics, medical imaging software, MRI analysis, neurodegenerative disease, AI diagnostics, Alzheimer's diagnosis, traumatic brain injury, automated segmentation, radiology software, clinical decision support, brain atrophy, medical device, neuroradiology, hippocampus volumetry, PACS integration, CE-marked, FDA-cleared, healthcare AI, neuroimaging, quantitative imaging